Search

Displaying results 3101 - 3110 of 10000 in total
  1. Drug

    Darusentan

    go.drugbank.com/drugs/DB04883
    Investigational

    Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.

  2. Drug

    Susoctocog alfa

    go.drugbank.com/drugs/DB11606
    ApprovedInvestigational

    AHA is a rare bleeding disorder that results in a prolonged clotting time as measured by the activated partial thromboplastin time (aPTT) assay, a conventional in vitro test for biological activity of … These autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this procoagulant protein.

  3. Drug

    Reboxetine

    go.drugbank.com/drugs/DB00234
    ApprovedInvestigationalWithdrawn

    Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. … Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.

  4. Drug

    Paramethadione

    go.drugbank.com/drugs/DB00617
    Approved

    Paramethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.

  5. Drug

    Diloxanide

    go.drugbank.com/drugs/DB08792
    Experimental

    Diloxanide (as [Diloxanide furoate]) is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections. … Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.

  6. Drug

    Aclidinium

    go.drugbank.com/drugs/DB08897
    Approved

    Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). … It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.

  7. Drug

    Fuzapladib

    go.drugbank.com/drugs/DB19478
    Experimental

    Fuzapladib has a monoisotopic molecular weight of 379.12 Da. … Fuzapladib is a small molecule drug. The usage of the INN stem '-pladib' in the name indicates that Fuzapladib is a phospholipase A2​ inhibitor.

    Categories: Phospholipase A2 Inhibitors, Phospholipases A, antagonists & inhibitors
  8. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [A249920] LetibotulinumtoxinA is a type A botulinum neurotoxin produced from fermentation of _Clostridium botulinum_ strain CBFC26. … [L42330] LetibotulinumtoxinA has been a market-leading cosmetic product in South Korea for a number of years and was subsequently approved in the European Union.

    Categories: Botulinum Toxins, Type ASynonyms: BoNT/A-DS
  9. Drug

    Pentamorphone

    go.drugbank.com/drugs/DB20947
    Experimental

    Pentamorphone is a small molecule drug. Pentamorphone has a monoisotopic molecular weight of 368.21 Da.

    Categories: Heterocyclic Compounds with 4 or More Rings
  10. Drug

    Eslicarbazepine acetate

    go.drugbank.com/drugs/DB09119
    ApprovedInvestigational

    Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. It is available in 200, 400, 600, or 800mg tablets that are taken once daily, with or without food. … Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled